Latest Ratios: P/E Ratio -1.7x · EV/EBITDA N/A · ROE -46.4%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $59M | $140M | $61M | $18M | $10M | $8M | — | — |
| Enterprise Value | $-7301001 | $74M | $-32873644 | $4M | $-25037325 | $-42096757 | — | — |
| P/E Ratio → | -1.68 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.00 | 2.31 | 0.64 | 1.52 | 0.30 | 0.16 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -46.4% | -46.4% | -49.9% | -102.8% | -35.7% | -66.7% | — | — |
| ROA | -43.4% | -43.4% | -46.8% | -88.7% | -33.2% | -40.4% | 1793.5% | -2333.8% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -50.9% | -50.9% | -55.8% | -107.5% | -37.0% | -53.7% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.09 | -0.99 | -1.22 | -1.02 | -1.03 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -27.19 | -161.78 | -3.89 | -4.80 |
Net cash position: cash ($66M) exceeds total debt ($112064)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.52 | 8.52 | 35.62 | 3.83 | 11.80 | 16.90 | 0.04 | 0.01 |
| Quick Ratio | 8.52 | 8.52 | 35.62 | 3.83 | 11.80 | 16.90 | 0.04 | 0.01 |
| Cash Ratio | 8.23 | 8.23 | 34.36 | 3.45 | 11.07 | 16.36 | 0.04 | 0.01 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $95M | $58M | $16M | $16M | $3M | $11M | $11M |
Clinical trial execution risk
As reported in financial statements, the company trades at a price-to-book ratio of 0.94, which suggests that the market is currently valuing the firm at a discount to its net cash position, potentially ignoring the long-term optionality inherent in the PR-antagonist and CLDN6 bispecific antibody programs.
The current P/B ratio below parity indicates that investors are assigning little to no value to the company's intellectual property or clinical pipeline beyond the liquidation value of its cash. This valuation gap warrants further investigation into whether the market is mispricing the potential of the progesterone receptor as a therapeutic target compared to more crowded ER-targeting programs.
Based on reported figures, the company's ROIC has fluctuated significantly, reaching -14.4% in 2025Q2, which reflects the inherent difficulty of generating positive returns on invested capital while the firm remains in a pre-revenue, clinical-stage development phase with no commercialized products to offset R&D expenditures.
The negative trend in ROIC is a structural reality for a firm that expenses all development costs immediately rather than capitalizing them. Investors should monitor whether the transition to more complex bispecific antibody development will further depress these returns or if potential milestone payments can provide a temporary offset to the ongoing capital erosion.
According to recent SEC filings, the company maintains a current ratio of 8.96 as of 2026Q1, which provides a substantial liquidity buffer that appears to be significantly stronger than many peers who rely on venture debt to sustain their operations during the high-cost clinical trial phase.
The high current ratio is primarily a function of the company's cash-heavy balance sheet and lack of significant short-term liabilities. While this position is currently adequate, the rapid burn rate observed in recent quarters suggests that this liquidity is a finite resource that must be managed carefully to avoid dilutive financing before critical data readouts.
As indicated by the provided financial data, the use of P/E ratios to evaluate this business is fundamentally flawed, as the company lacks commercial revenue and is currently in a phase where net losses are a direct result of necessary investment in future clinical trial success.
Investors often misapply P/E or EBITDA multiples to clinical-stage biotech, which obscures the reality that these metrics are designed for mature, cash-generating firms. A more appropriate analytical framework would focus on the cash-to-burn ratio and the probability-weighted net present value of the pipeline, rather than attempting to derive value from currently negative earnings.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CNTX stock.
Context Therapeutics Inc.'s current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.
Context Therapeutics Inc.'s return on equity (ROE) is -46.4%. The historical average is -60.3%.
Based on historical data, Context Therapeutics Inc. is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.